The Role and Intervention of TGF-β in Abdominal Radiation Injury

Inclusion Criteria: 1. Informed consent form for this study has been signed 2. Age 18-70 years old, gender is not limited，Pathological diagnosis of patients with advanced malignant tumors，Radiotherapy indications； 3. BED (α/β=10)≥50；ECOG score 0-2；Blood routine：WBC≥3.5×109/L,GRAN≥2.0×109/L,Hb≥90g/L，PLT≥100×109/L; 4. Liver function: ALT or AST ≤ 2.5 times the normal high value (ULN)；Bilirubin ≤ 1.5 × ULN, serum APK ≤ 2.5 × ULN; 5. Renal function：Serum creatinine ≤1.5×ULN, and creatinine clearance ≥60ml/min 6. No organ transplant history 7. Women of childbearing age must undergo a urine pregnancy test within 7 days prior to initiation of treatment and the results are negative and not in lactation 8. Male and female patients of childbearing age agreed to adopt a reliable method of contraception before entering the trial and during the study until 30 days after stopping the drug. Exclusion Criteria: 1. Patients undergoing chemotherapy or targeted therapy at the same time 2. Long-term use of ACEI or ARB drugs for hypertension 3. This radiotherapy site has been treated with radiotherapy；Combined with severe heart disease or major organ failure 4. Have a history of drug abuse or alcohol addiction 5. Combined active infection 6. Combined with severe malnutrition or severe anemia 7. Human immunodeficiency virus (HIV) infection 8. During pregnancy or lactation 9. Those who are unable to tolerate or may be allergic to the drugs used in this study；Persons without civil capacity or limited capacity for civil conduct； 10. Researchers believe that it is not suitable for inclusion